Markers of imminent myocardial infarction
Nature Cardiovascular Research, 2024
Gustafsson S., Lampa E., Jensevik Eriksson K., Butterworth A., Elmståhl S., Engström G., Hveem K., Johansson M., Langhammer A., Lind L., Läll K., Masala G., Metspalu A., Moreno-Iribas C., Nilsson P., Perola M., Simell B., Sipsma H., Åsvold B., Ingelsson E., Hammar U., Ganna A., Svennblad B., Fall T., Sundström J.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD | Pathophysiology Patient Stratification | Plasma |  Olink Target 96 |
Abstract
Myocardial infarction is a leading cause of death globally but is notoriously difficult to predict. We aimed to identify biomarkers of an imminent first myocardial infarction and design relevant prediction models. Here, we constructed a new case–cohort consortium of 2,018 persons without prior cardiovascular disease from six European cohorts, among whom 420 developed a first myocardial infarction within 6 months after the baseline blood draw. We analyzed 817 proteins and 1,025 metabolites in biobanked blood and 16 clinical variables. Forty-eight proteins, 43 metabolites, age, sex and systolic blood pressure were associated with the risk of an imminent first myocardial infarction. Brain natriuretic peptide was most consistently associated with the risk of imminent myocardial infarction. Using clinically readily available variables, we devised a prediction model for an imminent first myocardial infarction for clinical use in the general population, with good discriminatory performance and potential for motivating primary prevention efforts.